Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Droplet digital PCR (ddPCR)-based blood detection of EGFR mutations plays significant roles in the individualized therapy of non-small-cell lung cancer (NSCLC) patients. However, a standard assay that is approved by health authorities is still lacking. Additionally, the proper application of this method in clinical settings also needs further investigation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>The performance of a newly established ddPCR assay was first evaluated using reference samples and then validated by comparing this method with the amplification refractory mutation system (ARMS) using cell-free DNA (cfDNA) in patients' peripheral blood. Further, the correlation between dynamic quantification of EGFR mutation in the patients and their clinical outcome of tyrosine kinase inhibitors (TKIs) therapy was investigated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>A total of 77 patients were included, with 50 in the test group and 27 in the validation group. According to the results of the reference samples and the blood samples in the test group, the cut-off value for patient detection was proposed as mutation rate ≥ 0.1% (total copy number of cfDNA ≥1,000) or at least one copy of mutation DNA was detected (total copy number of cfDNA <1,000). With this criterion, superior sensitivity of our assay to that of ARMS was observed (<em>P</em>=0.002 for Ex19Del & L858R and <em>P</em><0.001 for T790M). The dynamic quantification of EGFR mutations during TKI therapy indicated that an increase in mutation abundance was correlated with resistance, while a decline was associated with response. Notably, a rebound in mutation abundance during chemotherapy may indicate a desirable chance for TKI re-treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>The novel ddPCR assay showed superior sensitivity in the detection of EGFR mutation in blood. The dynamic quantification of EGFR mutations by this assay would greatly facilitate the administration of TKI therapy, including the monitoring of resistance and response, as well as cohort screening for retreatment.</p>

Functional Detection of Dendritic Cells Induced from Human Umbilical Cord Blood CD34+ Cells in Vitro. Zhonghua Er Ke Za Zhi.

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Digital PCR analysis of plasma cell-free DNA for non-invasive detective of TKI targeted EGFR mutation in NSCLC patients

Establishment of a Digital PCR Platform for Detection of EGFR T790M Mutation in Plasma Circulating DNA from NSCLC Patients

Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients

Multiplex Picoliter-Droplet Digital PCR for Quantitative Assessment of EGFR Mutations in Circulating Cell-Free DNA Derived from Advanced Non-Small Cell Lung Cancer Patients

A Circulating Tumor Cell-Based Digital Assay for the Detection of EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancer

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

[The Detection by Denaturing High Performance Liquid Chromatography of Epidermal Growth Factor Receptor Mutation in Tissue and Peripheral Blood from Patients with Advanced Non-Small Cell Lung Cancer].

Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer

Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays

Detection of EGFR Gene with a Droplet Digital PCR Chip Integrating a Double-Layer Glass Reservoir.

Quantification Of Mutant Alleles In Circulating Tumor Dna Can Predict Survival In Lung Cancer

Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis

EGFR mutation detection of lung circulating tumor cells using a multifunctional microfluidic chip

Ultrasensitive and Quantitative Detection of EGFR Mutations in Plasma Samples from Patients with Non-Small-cell Lung Cancer Using a Dual PNA Clamping-Mediated LNA-PNA PCR Clamp

Comparison of Egfr Signaling Pathway Somatic Dna Mutations Derived from Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Droplet Digital PCR Based Detection of EGFR Mutations in Advanced Lung Cancer Patient Liquid Biopsies: A Comparison of Circulating Tumour DNA Extraction Kits

Cross-Platform Comparison Of Four Leading Technologies For Detecting Egfr Mutations In Circulating Tumor Dna From Plasma Of Patients With Non-Small Cell Lung Carcinoma

Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases

Detection of Circulating Tumor Cells and EGFR Mutation in Pulmonary Vein and Arterial Blood of Lung Cancer Patients Using a Newly Developed Immunocytology-Based Platform